Iguana Healthcare Management Increased Biogen (BIIB) Position by $3.91 Million; Oaktop Capital Management Ii LP Has Increased Its Position in Egain Com New (EGAN) by $1.00 Million

February 21, 2018 - By wolcottdaily

Oaktop Capital Management Ii Lp increased its stake in Egain Corp Com New (EGAN) by 24.55% based on its latest 2017Q3 regulatory filing with the SEC. Oaktop Capital Management Ii Lp bought 500,000 shares as the company’s stock declined 23.81% while stock markets rallied. The hedge fund held 2.54M shares of the prepackaged software company at the end of 2017Q3, valued at $6.85 million, up from 2.04M at the end of the previous reported quarter. Oaktop Capital Management Ii Lp who had been investing in Egain Corp Com New for a number of months, seems to be bullish on the $206.00 million market cap company. The stock increased 2.03% or $0.15 during the last trading session, reaching $7.55. About 49,370 shares traded. eGain Corporation (NASDAQ:EGAN) has declined 47.54% since February 21, 2017 and is downtrending. It has underperformed by 64.24% the S&P500.




Stuart Weisbrod increased its stake in Biogen Inc (BIIB) by 166.67% based on its latest 2017Q3 regulatory filing with the SEC. Iguana Healthcare Management Llc bought 12,500 shares as the company’s stock declined 13.45% while stock markets rallied. The hedge fund run by Stuart Weisbrod held 20,000 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $6.26M, up from 7,500 at the end of the previous reported quarter. Iguana Healthcare Management Llc who had been investing in Biogen Inc for a number of months, seems to be bullish on the $61.06 billion market cap company. The stock increased 0.40% or $1.14 during the last trading session, reaching $288.59. About 756,255 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since February 21, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 24 have Buy rating, 0 Sell and 9 Hold. Therefore 73% are positive. Biogen Idec Inc. had 113 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bank of America on Wednesday, October 18. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Buy” rating by H.C. Wainwright on Tuesday, August 11. The rating was downgraded by Credit Suisse on Thursday, January 25 to “Hold”. The rating was maintained by BMO Capital Markets on Monday, July 17 with “Hold”. On Thursday, March 16 the stock rating was downgraded by Leerink Swann to “Market Perform”. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by Robert W. Baird on Friday, March 11. The firm has “Buy” rating given on Thursday, January 25 by BMO Capital Markets. The stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given on Wednesday, August 30 by Jefferies. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Outperform” rating by RBC Capital Markets on Wednesday, October 7. The firm earned “Buy” rating on Thursday, January 18 by Piper Jaffray.

Since January 9, 2018, it had 0 insider purchases, and 1 sale for $1.92 million activity.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It increased, as 59 investors sold BIIB shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. First Midwest Bancshares Division invested in 0.11% or 2,838 shares. Auxier Asset Mgmt holds 28,145 shares or 1.79% of its portfolio. Baystate Wealth Mngmt Ltd Liability Corp holds 1,513 shares or 0.08% of its portfolio. Eaton Vance Mgmt owns 448,373 shares. Moreover, Old Mutual Customised Solutions (Proprietary) has 0.33% invested in Biogen Inc. (NASDAQ:BIIB). Gargoyle Investment Advisor Limited Co accumulated 0.26% or 2,247 shares. Capital Planning Llc holds 0.14% in Biogen Inc. (NASDAQ:BIIB) or 1,133 shares. Tokio Marine Asset Management holds 0.41% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 8,649 shares. Forbes J M And Llp reported 0.24% in Biogen Inc. (NASDAQ:BIIB). Bender Robert & Associates reported 1.73% in Biogen Inc. (NASDAQ:BIIB). 1,592 are held by Winslow Evans And Crocker. Millennium Limited Company invested 0.09% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Fdx holds 4,942 shares or 0.04% of its portfolio. Nikko Asset Management Americas stated it has 900 shares or 0.01% of all its holdings. Exane Derivatives holds 0.04% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 710 shares.

Iguana Healthcare Management Llc, which manages about $139.00M and $183.53M US Long portfolio, decreased its stake in Achaogen Inc (NASDAQ:AKAO) by 30,000 shares to 30,000 shares, valued at $479,000 in 2017Q3, according to the filing. It also reduced its holding in Avexis Inc by 12,500 shares in the quarter, leaving it with 17,500 shares, and cut its stake in Anaptysbio Inc.

Among 5 analysts covering eGain Comm. (NASDAQ:EGAN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. eGain Comm. had 10 analyst reports since August 4, 2015 according to SRatingsIntel. The company was upgraded on Friday, February 9 by Benchmark. As per Monday, October 2, the company rating was upgraded by Craig Hallum. The firm has “Buy” rating given on Tuesday, January 16 by Roth Capital. As per Friday, September 9, the company rating was upgraded by Ladenburg Thalmann. On Friday, September 9 the stock rating was maintained by Benchmark with “Hold”. As per Monday, May 9, the company rating was downgraded by Ladenburg Thalmann. Needham maintained the shares of EGAN in report on Friday, September 11 with “Buy” rating. The stock of eGain Corporation (NASDAQ:EGAN) earned “Hold” rating by Craig Hallum on Tuesday, August 4. The stock has “Neutral” rating by Ladenburg Thalmann on Thursday, November 10. The firm earned “Hold” rating on Monday, February 13 by Benchmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts